测试版
试验雷达 AI
临床试验 NCT06904027 针对尿素循环障碍目前招募中。请查看临床试验雷达卡片视图和 AI 发现工具了解所有详情,或在此提出任何问题。
一个试验符合筛选条件
卡片视图

A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders 40 多中心 儿科 罕见病

招募中
临床试验详情主要以英语提供。然而,试验雷达 AI可以提供帮助!只需点击“试验详解”即可查看和讨论您选择的语言的试验信息。
临床试验NCT06904027是一项针对尿素循环障碍观察研究试验,目前试验状态为招募中。试验始于2025年12月9日,计划招募40名患者。该研究由Tongji Hospital主导,预计于2031年7月1日完成。试验数据来源于ClinicalTrials.gov,最后更新时间为2026年1月15日
简要概括
Urea cycle disorders (UCD) are rare diseases in China, would lead to high mortality and disability, which require long-term management due to the recurrent symptoms. This multi-center, prospective, single-arm study was designed to assess the efficacy and safety of Glycerol Phenylbutyrate for Chinese pediatric patients with UCD, to provide the additional references and treatment options for Chinese UCD patients, and e...显示更多
详细描述
The duration of treatment with GPB in this study was 5 years. Forty participants aged 0-18 years with a diagnosis of UCD, including carbamoyl phosphate synthetase I deficiency, ornithine carbamoyltransferase deficiency, citrullinemia type I, argininosuccinic aciduria, argininemia, or hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, and who plan to use and have not used glycerol phenylbutyrate in the...显示更多
官方标题

A Single-arm, Prospective, Multi-center Post-market Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders

疾病
尿素循环障碍
其他研究标识符
  • WH002A401
NCT编号
实际开始日期
2025-12-09
最近更新发布
2026-01-15
预计完成日期
2031-07
计划入组人数
40
研究类型
观察研究
试验状态
招募中
关键词
Chinese
Pediatric patients
Urea cycle disorders
Glycerol phenylbutyrate
试验组/干预措施
参与者组/试验组干预措施/治疗方法
Glycerol phenylbutyrate cohort
Glycerol Phenylbutyrate was used.
Glycerol phenylbutyrate Oral Liquid
Administration and dosage: The recommended total daily dose of glycerol phenylbutyrate is calculated based on the patient's body surface area, ranging from 4.5 mL/m2/d to 11.2 mL/m2/d: 1. Recommended initial dose in phenylbutyrate-naïve patients * Patients with body surface area (BSA) \< 1.3 m2: 8.5 mL/m2/day * Patients with body surface area (BSA) ≥ 1.3 m2: 7 mL/m2/day 2. Initial dose for patients switching ...显示更多
主要终点
结果指标度量标准描述时间框架
Mean blood ammonia levels at month 3 after enrollment.
The average of blood ammonia levels at months 3 after enrollment.
months 3
次要终点
结果指标度量标准描述时间框架
Mean blood ammonia levels
The average of blood ammonia levels at period of baseline, month 1, month 6, and every 6 months thereafter (1-5 years)
Baseline, Month 1, Month 6, and every 6 months thereafter (1-5 years)
Maximum blood ammonia levels
The maximum blood ammonia levels at period of baseline, month 1, month 3, month 6, and every 6 months thereafter (1-5 years)
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)
Frequency of hyperammonaemic crisis
The frequency of hyperammonaemic crisis at period of baseline, month 1, month 3, month 6, and every 6 months thereafter (1-5 years)
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)
Height
The change of height to the baseline in children aged 0-18 years old, and the proportion of weight in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old (WS/T 423-2022) and standard for height level classification among children and adolescents aged 7\~18 years (WS/T 612-2018)issued by the National Health Commission of the People's Republic of China.
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years).
Weight
The change of weight to the baseline in children aged 0-7 years old, and the proportion of weight in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old issued by the National Health Commission of the People's Republic of China (WS/T 423-2022).
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)
Head circumference
The change of head circumference to the baseline in children aged 0-3 years old, and the proportion of head circumference in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old issued by the National Health Commission of the People's Republic of China (WS/T 423-2022).
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)
Dose adjustment changes
The changes of dose adjustment in glycerol phenylbutyrate throughout the study
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)
Mean Neonatal Behavioral Neurological Assessment Scores: Behavioral ability, passive muscle tone, active muscle tone, primitive reflexes, and general assessment
The neonatal behavioral neurological assessment (NBNA) scale was used for newborn participants who were at least 2 months of age, consisting of 20 items, with a maximum score of 40 points. The total scores of the NBNA are derived from the cumulative sum of the scores obtained in behavioral ability (6 items), passive muscle tone (4 items), active muscle tone (4 items), primitive reflexes (3 items), and general assessment (3 items), which are collected according to the scales have been actually completed by the subjects in the clinical practice. The total scores greater than 37 is considered normal, while a score less than or equal to 37 is considered abnormal.
Month 6, every year thereafter (1-5 years)
Mean Bayley Scale of Infant Development Scores: mental scale, motor scale
The Bayley Scale of Infant Development was used for infant participants whose ages range from 2 months to 30 months, consisting of 244 behavioral items, including 163 items on the mental scale and 81 items on the motor scale. The scores of each infant on the mental and motor scales are converted into standard scores with a mean of 100 and a standard deviation of 16 according to age groups, thereby calculating the Mental Development Index (MDI) and the Psychomotor Development Index (PDI). A total score of MDI and PDI, which are collected according to the scales have been actually completed by the subjects in the clinical practice, are less than 70 indicates developmental delay, 70-79 indicates a borderline state, 80-89 indicates low average, 90-109 indicates average, 110-119 indicates high average, 120-129 indicates superior, and a score of 130 or above indicates very superior.
Month 6, every year thereafter (1-5 years)
Mean Gesell Developmental Diagnosis Scale Scores
The assessment for Gesell Developmental Diagnosis Scale Scores was used for participants whose ages range from 30 months to 6 years, including five areas: gross motor skills, fine motor skills, adaptive behavior, language, and personal-social behavior. The observed behavioral patterns are identified based on the standard of normal behavioral patterns and are expressed in terms of age. This age is then compared with the actual age to calculate the Developmental Quotient (DQ), which is DQ = Developmental Age / Actual Age × 100, and the values of DQ are collected according to the scales have been actually completed by the subjects in the clinical practice. A DQ of 85 or above is considered normal for the nervous system, a DQ between 75 and 85 (inclusive of 75 but exclusive of 85) indicates a borderline level of nervous system impairment, and a DQ below 75 indicates nervous system damage.
Month 6, every year thereafter (1-5 years)
Mean Wechsler Preschool and Primary Scale of Intelligence Scores: The Verbal Intelligence Quotient, the Performance Intelligence Quotient
The Chinese - Wechsler Preschool and Primary Scale of Intelligence (C - WYCSI) was used for children participants whose ages range from 4 to 6 years. The Verbal Intelligence Quotient (VIQ) test includes five subtests: Information, Picture Vocabulary, Arithmetic, Picture Comprehension, and Comprehension. The Performance Intelligence Quotient (PIQ) test includes five subtests: Animal Hatching, Picture Completion, Mazes, Geometric Shapes, and Block Design. The intelligence quotient (IQ) score obtained from the 10 subtests of VIQ and PIQ is the Full Intelligence Quotient (FIQ). The values for VIQ, PIQ and FIQ are collected according to the scales have been actually completed by the subjects in the clinical practice. FIQ is divided into five levels: ≥130 is superior, 116 - 129 is above average, 85 - 115 is average, 70 - 84 is below average, and \< 70 is intellectual disability.
Month 6, every year thereafter (1-5 years)
Mean Wechsler Intelligence Scale for Children Scores: The Verbal Intelligence Quotient, the Performance Intelligence Quotient
The Chinese-Wechsler intelligence scale of children (C-WISC)was used for participants whose ages range from 7 to 18 years. This scale consists of 11 subtests. The Verbal Intelligence Quotient (VIQ) test includes Information, Comprehension, Similarities, Arithmetic, Digit Span, and Vocabulary. The Performance Intelligence Quotient (PIQ) test includes Picture Completion, Picture Arrangement, Block Design, Object Assembly, and Coding. First, the raw score is calculated based on the test results of the examinee. Then, the corresponding age-specific scale score coefficient is checked and converted into a scale score. The sum of the VIQ and PIQ scale scores is the full intelligence quotient (FIQ) score, which are collected according to the scales have been actually completed by the subjects in the clinical practice. A FIQ of ≥120 is classified as high intelligence, 90-119 is classified as normal intelligence, and a score \< 90 is classified as low intelligence.
Month 6, every year thereafter (1-5 years)
参与助手
资格标准

适龄参与研究
儿童, 成人
最低年龄要求
0 Years
适龄性别
全部
  1. Male or female aged 0-18 years;
  2. Subject and/or subject's legally authorized representative willing to follow the therapeutic regimen, dietary management and visit plan of the study, and voluntarily signing informed consent form;
  3. Patients with the following subtypes of UCD: Carbamoyl phosphate synthetase I deficiency, Ornithine translocase deficiency, citrullinemia type I, argininosuccinic aciduria, argininemia, and hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome;
  4. Patients planned to use glycerol phenylbutyrate who have not used it in past 3 months (including at the time of 3 months);
  5. Men with fertility and women of childbearing potential (with menstruation) who are willing to take effective contraceptive measures during the period from the date of signing the informed consent to 1 months after the last dose of the study drug, such as abstinence, condoms, intra-uterine contraceptive devices, and double barrier methods (such as condoms + contraceptive diaphragms). Pregnancy test results must be negative for women of childbearing age within ≤ 7 days before the initial administration of study drug.

  1. Hypersensitivity to any of the active ingredient, including phenylbutyrate (PBA), phenylacetate acid (PAA) and phenylacetyl glutamine (PAGN), or excipients;
  2. Use of any drug known to significantly affect renal clearance (such as probenecid) or increase protein catabolism (such as corticosteroids) or other drugs known to increase blood ammonia levels (such as valproate) within 24 h before the first administration;
  3. Use of other nitrogen-scavenging agent at the same time after enrollment, such as sodium phenylbutyrate and sodium benzoate;
  4. Pregnant or breastfeeding females.
  5. Other reasons, in the opinion of the investigator, that may affect the patient's compliance and safety in participating in the study.
Tongji Hospital logoTongji Hospital
研究责任方
Xiaoping Luo, 主要研究者, Professor, Tongji Hospital
研究中心联系人
联系人: Xiaoping Luo, M.D., 027-83662640, [email protected]
5 位于 1 个国家/地区的研究中心

Beijing Municipality

Peking University First Hospital, Beijing, Beijing Municipality, 100034, China
Yang, M.D., 联系人, 010-83572211, [email protected]
招募中

Guangdong

Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, 510000, China
Liu, M.D., 联系人, 020-81886332, [email protected]
招募中

Hubei

Tongji Hosipital, Wuhan, Hubei, 430030, China
Luo, M.D., 联系人, 027-83662640, [email protected]
招募中

Shanghai Municipality

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, 200092, China
Qiu, M.D., 联系人, 021-2507 8999, [email protected]
招募中

Zhejiang

Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Dong, M.D., 联系人, 0571-87061007, [email protected]
尚未招募